Expand JBIO Menu
JBIO MENU

JBIO Latest Press Releases

-- January 5, 2026 --

Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference Globe Newswire 7:00 AM

-- December 15, 2025 --

Jade Biosciences Announces $45 Million Private Placement Globe Newswire 7:00 AM

-- November 13, 2025 --

Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update Globe Newswire 4:05 PM

-- November 8, 2025 --

Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025 Globe Newswire 11:00 AM

-- November 3, 2025 --

Jade Biosciences to Participate in Upcoming Conferences Globe Newswire 7:00 AM

-- October 17, 2025 --

Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025 Globe Newswire 4:05 PM

-- October 7, 2025 --

Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases Globe Newswire 7:05 AM
Jade Biosciences Announces $135 Million Private Placement Globe Newswire 7:00 AM

-- September 2, 2025 --

Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy Globe Newswire 7:00 AM

-- August 25, 2025 --

Jade Biosciences to Participate in Upcoming Conferences Globe Newswire 7:00 AM

-- August 13, 2025 --

Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update Globe Newswire 4:05 PM
Market Data Delayed 15 Minutes